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Abstract
Background: Increasing rates of type 2 diabetes mellitus place a substantial burden on health care services,
communities, families and individuals living with the disease or at risk of developing it. Estimates of the combined
prevalence of intermediate hyperglycaemia and diabetes in Bangladesh vary, and can be as high as 30% of the
adult population. Despite such high prevalence, awareness and control of diabetes and its risk factors are limited.
Prevention and control of diabetes and its complications demand increased awareness and action of individuals
and communities, with positive influences on behaviours and lifestyle choices. In this study, we will test the effect
of two different interventions on diabetes occurrence and its risk factors in rural Bangladesh.
Methods/design: A three-arm cluster randomised controlled trial of mobile health (mHealth) and participatory
community group interventions will be conducted in four rural upazillas in Faridpur District, Bangladesh. Ninety-six
clusters (villages) will be randomised to receive either the mHealth intervention or the participatory community
group intervention, or be assigned to the control arm. In the mHealth arm, enrolled individuals will receive twice-
weekly voice messages sent to their mobile phone about prevention and control of diabetes. In the participatory
community group arm, facilitators will initiate a series of monthly group meetings for men and women,
progressing through a Participatory Learning and Action cycle whereby group members and communities identify,
prioritise and tackle problems associated with diabetes and the risk of developing diabetes. Both interventions will
run for 18 months. The primary outcomes of the combined prevalence of intermediate hyperglycaemia and
diabetes and the cumulative 2-year incidence of diabetes among individuals identified as having intermediate
hyperglycaemia at baseline will be evaluated through baseline and endline sample surveys of permanent residents
aged 30 years or older in each of the study clusters. Data on blood glucose level, blood pressure, body mass index
and hip-to-waist ratio will be gathered through physical measurements by trained fieldworkers. Demographic and
socioeconomic data, as well as data on knowledge of diabetes, chronic disease risk factor prevalence and quality of
life, will be gathered through interviews with sampled respondents.
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Discussion: This study will increase our understanding of diabetes and other non-communicable disease burdens
and risk factors in rural Bangladesh. By documenting and evaluating the delivery, impact and cost-effectiveness of
participatory community groups and mobile phone voice messaging, study findings will provide evidence on how
population-level strategies of community mobilisation and mHealth can be implemented to prevent and control
noncommunicable diseases and risk factors in this population.
Trial registration: ISRCTN41083256. Registered on 30 Mar 2016 (Retrospectively Registered).
Trial acronym: D-Magic: Diabetes Mellitus – Action through Groups or mobile Information for better Control.
Keywords: Diabetes, Intermediate hyperglycaemia, mHealth, Community mobilisation, Cluster randomised trial,
Non-communicable disease,
Background
The global health importance of diabetes mellitus
Globally, type 2 diabetes mellitus (T2DM) and its complica-
tions are a growing concern among communities, health
service providers and policymakers. The global prevalence
of T2DM was estimated to be approximately 9% among
adults in 2015, with around 75% of people living with
T2DM in low- and middle-income countries [1]. Increasing
rates of T2DM place a substantial burden on overstretched
health care services, communities, families and individuals
living with the disease or at risk of developing it. T2DM
can lead to premature death; greatly increases the risk of
cardiovascular disease; and, if not managed properly, can
lead to serious morbidities, including nerve and renal
complications [2]. Underlying the increasing prevalence of
T2DM are complex genetic, environmental and lifestyle
factors, including dietary changes and increases in risk
factors such as smoking and lack of exercise.
T2DM in Bangladesh
The Bangladesh Demographic and Health Survey
(BDHS) of over 17,000 households across Bangladesh
found that approximately 25% of people aged 35 years
or older in rural areas had abnormal fasting glucose and
approximately 11% were diabetic [3]. Analysing the data
from the BDHS, Akter et al. [4] reported a higher preva-
lence of T2DM among older people but no significant
differences between males and females. There was a sig-
nificant difference between the poorest and richest
households in diabetes prevalence (6.4% of the poorest
households and 19.2% richest households); the difference
was considerably lower for impaired fasting glucose
levels (19.7% and 23.5%, respectively) [4]. Although the
prevalence of diabetes was considerably higher in urban
households (15.2%) than in rural households (8.3%), for
impaired fasting glucose, the prevalence was slightly
higher for rural households (23.5%) than for urban
households (19%). Other studies have shown lower levels
of dysglycaemia, with Bhowmik et al. [5, 6] reporting a
combined 2009 prevalence of impaired fasting glucose
and T2DM of around 12–13% among adults aged
20 years or older in the rural but urbanising Chandra
District, close to Dhaka. Sayeed et al. [7] estimated the
prevalence of impaired fasting glucose and T2DM to be
approximately 17% in adults aged 20 years and older in
rural Mymensingh District, although trend data suggest
that the prevalence is now higher [5, 7, 8]. In a systematic
review and meta-analysis of studies on cardiovascular dis-
eases and T2DM in Bangladesh, Saquib et al. [9] estimated
the prevalence of diabetes in the period 2006–2010 to be
9%, though their data suggest a lower prevalence for rural
areas, and the overall prevalence described between 1995
and 2010 ranged from 2% to more than 21%, with a
pooled prevalence of 6.7% [9]. The prevalence of impaired
fasting glucose and impaired glucose tolerance were esti-
mated to be 7% and 8.2%, respectively, when data from all
studies were pooled. More recently, Islam et al. [10] esti-
mated the prevalence of T2DM in rural Narail District to
be 7.2% and impaired fasting glucose to be 5.3%. The
scant representative epidemiological data and conflicting
estimates of disease prevalence highlight a need for large-
scale, community-based surveys in rural Bangladesh,
where, at present, prevalence estimates of intermediate
hyperglycaemia and T2DM range between 12% and 30%,
with apparent regional differences.
Few studies have described the incidence of diabetes in
South Asia, although Asghar et al. [8] estimated the inci-
dence among adults older than 20 years of age in rural
Bangladesh between 1999 and 2004 to be 16.4 per 1000
person-years, increasing to 49 per 1000 person-years when
adjusted for the age and sex distributions of their sample.
Their data show that the incidence among individuals
with impaired fasting glucose is approximately four times
higher than among the total population; thus, the inci-
dence of T2DM among these individuals can be estimated
to be as high as 20% per year.
Despite the high levels of T2DM and intermediate
hyperglycaemia, awareness and control of the condition
are limited. The BDHS survey found that 59% and 65%
of affected women and men, respectively, were not
aware of their elevated blood glucose levels and that only
37% of diabetic women and 31% of diabetic men were
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taking medication for their diabetes, with only 15% of
women and 10% of men adequately controlling their
blood glucose levels [3]. Reasons for low levels of aware-
ness of one’s diabetic status and control of it include in-
adequate health services for diagnosing and treating
diabetes effectively, not being able to afford regular
health care and treatment, and communicable diseases
remaining a priority for Bangladeshi health programmes
[11]. Additionally, those who are less educated and of
lower socio-economic status are significantly less likely
to have their T2DM diagnosed and treated [11]. A study
by Islam et al. [10] on knowledge of T2DM and gly-
caemic control among patients with T2DM in Dhaka
found that 45.6% of patients in the study had good
knowledge of diabetes, 37.7% had moderate knowledge
of it and 16.7% had poor knowledge. Whereas the ma-
jority of respondents in the study identified changing
lifestyle and diet as important to managing diabetes, spe-
cifics such as excessive sugar intake were not recognised
as a risk factor, and the importance of exercise was iden-
tified as important by only 24.3% of respondents. In a
separate study in rural Bangladesh, knowledge that dia-
betes can cause eye disease and can be controlled by
regular exercise was found to be higher among men than
among women [12]. Knowledge of diabetes prevention,
control, consequences and risk factors has been found to
be significantly associated with higher education, higher
monthly income, family history of diabetes and a longer
duration of a diagnosis of T2DM [10, 12].
The need for further research and interventions
Research is needed to accurately describe the prevalence
and patterns of T2DM, intermediate hyperglycaemia and
risk factors for developing T2DM in rural Bangladesh.
Although evidence demonstrates that lifestyle and other
non-pharmacological interventions can prevent and
delay the onset of T2DM [13], there is a lack of cost ef-
fective programs designed specifically for Bangladeshi
populations, mindful of their own needs and resources.
Mobile health
One such approach is mobile health (mHealth), broadly
defined as the application of mobile technology to im-
prove health and strengthen health systems. There is evi-
dence that mHealth techniques can increase adherence
to medication in those already diagnosed with a chronic
disease [14]. There is also some evidence of mHealth in-
fluencing behaviour change. Authors of a review of 14
intervention studies (in the United States, Europe,
Australasia and South Korea) specifically on phone mes-
sages used to decrease obesity found that 11 of the stud-
ies using short message service (SMS) messages had a
statistically significant effect on weight loss, diet or exer-
cise, though the interventions did differ substantially and
questions remain about long-term impact [15]. Authors
of a review of over 100 studies done over the last
25 years on chronic disease management and mHealth
found that mobile messaging could assist with medicine
adherence, although the results for chronic disease man-
agement were mixed, and more research into under-
standing and improving mHealth tools is needed [14].
Evidence of the effectiveness of mHealth interventions
in low- and middle-income settings is mixed, with many
lacking thorough evaluations [16, 17]. Of the mHealth
interventions targeting T2DM in South Asia, a pilot
study with patients with T2DM who received 1 year of
SMS messaging regarding their treatment did reduce
glycaemic levels as compared with the control group in
India [18]. Ramachandran et al. [19] showed that the re-
ceipt of two to four mobile phone text messages per
week with dietary and physical activity recommendations
reduced the 2-year cumulative incidence of T2DM
among professional men aged 35–55 years with impaired
glucose tolerance by more than one-third in an individ-
ual randomised trial in southeastern India. Thus, al-
though there is some evidence for mHealth having an
impact on behaviour change and diabetic outcomes in a
high-risk population, the effect at scale and in a general,
rural population are unknown.
Community mobilisation
There is good evidence for lifestyle interventions pre-
venting and/or delaying the onset of T2DM [13, 20], and
involving the community and peer support is a cost-
effective means of promoting lifestyle changes.
Community-based peer support as a method of T2DM
control intervention is starting to be tested in low-
income countries [20–24], and encouraging evidence is
emerging. However, relatively small sample sizes, short
intervention durations, focus on high-risk individuals
and the lack of a counterfactual limits interpretation of
cause and effect as well as potential impact at a general
population level.
A randomised control trial is currently being con-
ducted in Kerala, India [20]. Through group motivation
sessions, diabetes prevention education sessions, hand-
book and participant workbooks, its aims are to decrease
T2DM and to improve behavioural, psychosocial, clinical
and biomedical measures in the community. The results
of the 2-year intervention study are not yet available.
Community mobilisation through Participatory Learn-
ing and Action (PLA) is a specific approach to commu-
nity interventions that fosters community engagement in
the identification of problems and threats to their health,
the design and implementation of solutions to tackle
these problems, and reflecting on their success. This
approach has been shown to substantially improve
maternal and newborn health [25]. However, the PLA
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approach has not been tested on health issues beyond
pregnancy, childbirth, neonatal [26, 27] and child health
[28], and women’s and reproductive health [29].
Methods/design
Goals
The goals of the present study are to prevent intermedi-
ate hyperglycaemia1 and T2DM and to improve control
of T2DM in Bangladesh.
Objectives
The objectives of the present study are to design and im-
plement community mobilisation and mHealth interven-
tions for the prevention and control of diabetes in rural
Bangladesh and to test their effect on intermediate
hyperglycaemia and T2DM disease occurrence, manage-
ment and risk factors in the population.
Research questions and outcomes
Table 1 details all study research questions, outcome
measures and definitions.
Primary research questions
The following are the primary research questions of the
study:
1. What is the effect of a participatory community
mobilisation intervention on a) the prevalence
of intermediate hyperglycaemia and T2DM and
b) two year cumulative incidence of T2DM among
Table 1 Study outcomes and definitions
Outcome type Outcome Definition
Primary The prevalence of intermediate hyperglycaemia
and T2DM
Proportion of adults aged 30 years or older with WHO
categorisations for intermediate hyperglycaemia
(impaired fasting glucose or impaired glucose tolerance)
and T2DM
Two-year cumulative incidence of T2DM among
individuals with intermediate hyperglycaemia
at baseline
Proportion of adults aged 30 years or older with plasma
glucose cut-off categorisations for intermediate
hyperglycaemia at baseline who are categorised
as T2DM at endline
Secondary Blood pressure Mean population diastolic and systolic blood pressure
Prevalence of hypertension Proportion of adults aged 30 years or older with systolic
blood pressure ≥140 mmHg or diastolic blood pressure
≥90 mmHg or self-reported current treatment with
anti-hypertensive medication
Body mass index Mean population BMI
Prevalence of overweight and obesity Proportion of adults aged 30 years or older with a BMI
of 23 kg/m2 or more
Abdominal obesity Proportion of adult men and women aged 30 years
or older with waist-to-hip circumference ratio >0.9
or >0.85, respectively
Quality of life score Mean health-related quality of life (EQ-5D)
Psychological distress among self-reported diabetics Mean SRQ score among adults aged 30 years and
older with self-reported diabetes
Explanatory Physical activity Proportion of adults aged 30 years and older engaged
in 30 minutes or more of physical activity per day on
at least 5 days per week
Intake of fruit and/or vegetables Mean number of portions of fruit or vegetables
consumed per adult aged 30 years or older per day
Population knowledge about diabetes risk factors,
symptoms and complications
Proportion of adults aged 30 years and above who are
(a) able to name at least one cause of diabetes, (b) able
to report at least one symptom of diabetes, (c) able to
report at least one complication of diabetes, (d) able to
recognise complications of diabetes when prompted,
(e) able to report at least one way to reduce the risk
of getting diabetes and (f) able to report at least one
way to control diabetes if diagnosed
Self-awareness of diabetic status Proportion of diabetics who correctly report their
diabetic status
Receipt of treatment or advice for diabetes Proportion of diabetics receiving care or advice from
a medical professional
Abbreviations: BMI Body mass index, SRQ Self-Reporting Questionnaire, T2DM Type 2 diabetes mellitus, WHO World Health Organisation
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individuals with intermediate hyperglycaemia at
baseline?
2. What is the effect of an mHealth health promotion
and awareness intervention on a) the prevalence
of intermediate hyperglycaemia and T2DM and
b) two year cumulative incidence of T2DM among
individuals with intermediate hyperglycaemia at
baseline?
Ancillary questions
The following are ancillary questions of the study:
What is the effect of a) a participatory community
mobilisation intervention and b) an mHealth health
promotion and awareness intervention on population:
a. Blood pressure
b. Prevalence of hypertension
c. Body mass index
d. Prevalence of overweight and obesity
e. Prevalence of abdominal obesity
f. Health-related quality of life
g. Psychological distress among self-reported diabetics
Explanatory outcomes
In addition to the questions above, which will be an-
swered in terms of primary and secondary outcomes
(Table 1), five additional explanatory outcomes will be
measured to better understand intervention processes
and mechanisms of action in terms of changes in the
following:
1. Population physical activity levels
2. Population intake of fruit and vegetables
3. Population knowledge about diabetes risk factors,
symptoms and complications
4. Self-awareness of diabetic status
5. Proportion of diabetics receiving treatment or advice
for diabetes
Trial design overview
The mHealth and community mobilisation interventions
will be evaluated using a three-arm cluster randomised con-
trolled trial design. The rationale is that each intervention is
applied to the entire community and is not based on indi-
vidual enrolment. Ninety-six villages will be randomised to
either the mHealth intervention, community mobilisation or
the control arm, and, given the nature of the interventions,
allocation is not masked. Baseline and endline sample sur-
veys measuring the prevalence of intermediate hypergly-
caemia, diabetes, hypertension and various chronic disease
risk factors, quality of life, as well as knowledge and care-
seeking practices will be conducted before and after inter-
vention delivery, respectively. Individuals identified at
baseline as having intermediate hyperglycaemia will be
followed after the interventions to determine the incidence
of T2DM among this high-risk population.
Setting
Faridpur District has a population of over 1.7 million
people in an area of just over 2000 km2 and is situated
on the banks of the Padma River (Fig. 1). The district
has a mainly agricultural economy, with the main crops
being jute and rice. Large rivers throughout the district
are prone to flooding, which can hinder travel and
health care access in the area. The population is mainly
Bengali, as is the case in most of Bangladesh, and almost
90% of the population of Faridpur are Muslim, with the
remaining population largely Hindu. Administratively,
Faridpur District is divided into nine upazillas, which in
turn are divided into unions of approximately 25,000
population per union. The number of unions per upa-
zilla in Faridpur District varies from 4 to 17. Each union
is comprised of a number of mauzas, traditional admin-
istrative units that can be conceptualised as a village or
collection of villages. Four upazillas in Faridpur District
have been purposefully selected on the basis of being ac-
cessible to the district headquarters of the Diabetic As-
sociation of Bangladesh (BADAS) in Faridpur Sadar:
These are Boalmari, Saltha, Madhukhali and Nagar-
kanda. For each of these upazillas, the 2011 Bangladesh
Census [30] was used to identify all mauzas with at least
one village of between 750 and 2500 population size, 96
of which were selected for inclusion in the study.
In Bangladesh, primary care is provided by the govern-
ment at union health and family welfare centres and at com-
munity clinics. In- and outpatient services are provided at
subdistrict (upazilla) health complexes and hospitals, and
tertiary care is provided at district hospitals and medical col-
lege hospitals. Inadequate facilities and trained health care
providers, short supplies of medicines, and low responsive-
ness of services are challenges faced by the health care sys-
tem in Faridpur District. Private health care provision is also
available in Faridpur, including at the Diabetic Association
Medical College Hospital in Faridpur Sadar.
The trial is implemented by the BADAS Perinatal Care
Project (PCP), a non-profit, voluntary socio-medical or-
ganisation registered with the Ministry of Social Welfare
that works closely with the Government of Bangladesh
in collaboration with the Institute for Global Health,
University College London.
Study population
In intervention areas, the target group for the mHealth
and community mobilisation interventions are male and
female permanent residents aged 30 years or older be-
cause this is the group that we expect to benefit the
most from the community-level interventions. Note,
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however, that both interventions will be available and ac-
cessible to any community member, including health
care providers. People are considered permanent resi-
dents of a village if the house that they normally live in
is in that village. Temporary residents whose permanent
home is in a village not included in the study or in-
cluded in a different arm are not considered part of the
intervention target population.
Interventions
mHealth
The mHealth intervention will consist of twice-weekly
health behaviour-related and awareness-raising voice
messages sent to individuals’ mobile phones over a
period of 18 months. Message content will be based on
findings from formative research in the study area, appli-
cation of behaviour change theories, review by medical
experts and project staff, and specification of a creative
brief which will be used by scriptwriters to create mes-
sages in a range of formats, such as mini-dramas, dia-
logues and songs. These will be performed by actors and
recorded, and a signature jingle will be added to make
the messages recognisable as coming from BADAS-PCP.
Each message will be recorded in Bangla in Dhaka, and
recipients will receive distinct messages on two different
occasions each week during the 18-month intervention
period. Messages will be sent to all subscribed mobile
phones using a service provided by MWorld (Dhaka,
Bangladesh), a commercial third party.
The intervention will be available to all individuals
with access to a mobile phone in the study areas. Indi-
viduals will need to register for the messaging service by
providing their mobile phone number to community re-
cruiters. Recruiters will coordinate community engage-
ment activities, which will include community meetings,
and mass communication methods, such as posters, leaf-
lets, loudspeaker broadcasting and presentations at pub-
lic service points (e.g., markets, clinics, places of
worship). In addition to these recruitment drives, indi-
viduals will be able to self-enrol at any time throughout
the study period.
A behaviour change theory-based approach to the
mHealth intervention is likely to increase its chances of
working [19, 31]. As such, the intervention will be devel-
oped using the capability, opportunity, motivation and
behaviour (COM-B) theory for understanding behaviour
Fig. 1 Map of Faridpur District divided into nine upazillas (source: Local Government Engineering Department, Bangladesh)
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[32] and the Theoretical Domains Framework (TDF) to
encourage change [33, 34].
The COM-B framework focuses on the interaction be-
tween capability, opportunity and motivation to generate
behaviour. Capability is defined as an individual’s psy-
chological and physical capacity to engage in the activity
concerned. It includes having the necessary knowledge
and skills. Motivation is defined as all the brain
processes that energise and direct behaviour, not just
goals and conscious decision-making. It includes habit-
ual processes, emotional responding and analytical
decision-making. Opportunity is defined as all the factors
that lie outside the individual that make the behaviour
possible or prompt it. The different elements are inter-
related. For example, opportunity can influence motiv-
ation, as can capability; engaging in a behaviour can alter
capability, motivation and opportunity. The TDF frame-
work (which corresponds with COM-B) was developed
through consensus by behaviour change specialists and
has been validated and refined [33, 35]. The framework
simplifies and integrates existing behaviour change the-
ories to make them accessible. It identifies 14 overarch-
ing behavioural domains that can be mapped according
to capability, opportunity and motivation [35]. By cate-
gorising behaviour, different behaviour change techniques
can be drawn on in order to encourage behaviour change
[36]. Behavioural domains in the formative research that
correspond with specific barriers to and enablers of behav-
iour change (e.g., knowledge, environmental context, beliefs
about consequences) will be identified. In order to systemat-
ically address enablers and barriers, behaviour change tech-
niques, such as shaping knowledge, modelling behaviour,
and information about consequences, will be applied to the
messages. Application of COM-B and the TDF to formative
research and engagement with community members will in-
volve an element of ‘behavioural diagnosis’ whereby it will
be possible to identify areas of leverage for behaviour change
within our target population.
Whilst the precise details of the mHealth intervention
will emerge from the formative work, some general prin-
ciples and descriptors of the intervention using the
World Health Organisation (WHO) mHealth Technical
and Evidence Review Group standard taxonomy of
mHealth activities can be specified [37]. The target will
be health promotion and disease prevention for the
avoidance and continuous control of non-communicable
disease risk factors, particularly those associated with
T2DM, among the adult population using mobile phone
voice messages as a communication channel.
Community mobilisation
The community mobilisation intervention will be an adap-
tation of a participatory women’s group intervention im-
plemented and evaluated in several settings and shown to
be effective at reducing neonatal mortality [27, 25]. The
intervention will entail the initiation and facilitation of
separate male and female participatory groups comprising
approximately 20 members each. Groups will be open to
all community members of any age; however, people with
T2DM and high-risk individuals will be particularly en-
couraged to attend. Separate groups will be established for
men and women because this is the approach most likely
to achieve true participation within the rural Bangladeshi
context, and there will be an equal number of male and fe-
male groups within each community mobilisation inter-
vention cluster, with a minimum of one male and one
female group per cluster. Joint meetings of men’s and
women’s groups, as well as the wider community, will be
encouraged. Enough groups will be established to ensure
population coverage of approximately 1 group per 600
population or 1 group per 200 adults; however, the
requirement of at least one male and one female group
per cluster may increase population coverage beyond this
target.
The groups will proceed through a series of 18
monthly meetings and several wider community-level
meetings following the four phases of PLA (Fig. 2).
Phase 1 will be focused on problem identification,
whereby participants themselves identify and prioritise
factors that affect their health, specifically threats that
increase their risk of developing or failing to manage
diabetes. Phase 2 involves the collective design of strat-
egies that participants and their communities can imple-
ment to address the problems and threats identified in
phase 1. During phase 3, the participants and commu-
nity implement these strategies. In phase 4, the partici-
pants reflect on and evaluate the success of the
strategies they have implemented. Problems that might
be identified in phase 1 may include lack of awareness of
signs and symptoms of diabetes, limited opportunity for
physical exercise in a culturally appropriate or secure en-
vironment, or lack of choice in locally available food
types. The community-led strategies that might be im-
plemented may include large community meetings to
raise awareness, community-led exercise groups, or
cookery workshops highlighting healthier food types and
cooking methods. Each meeting will comprise a range of
activities using picture card games, discussion, role-
playing, and storytelling to raise awareness and improve
support, treatment and preventive behaviours for the
population as a whole and for individuals with T2DM
and their families. Those who attend groups will be en-
couraged to share their learning and key messages with
other members of the community who were unable to
attend, such as through household visits and establishing
links with other groups in the area.
Participatory groups will be led by salaried group facil-
itators, each required to coordinate and facilitate several
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participatory group meetings per month. All facilitators
will have a minimum of higher secondary school educa-
tion, will be recruited from the study areas, and will re-
ceive 1 week’s training on group facilitation and basic
health messages related to chronic disease prevention
and control, with a particular focus on T2DM. The facil-
itators will also be provided with a community facilitation
manual with essential information on T2DM as well as its
causes and control. The community facilitation manual
will be developed during the formative phase of the pro-
ject and will be aligned with national and international
standards and based on materials developed by BADAS.
Facilitators will be equipped with simple picture cards and
flip charts graphically conveying health messages to stimu-
late discussion and critical thinking. Male groups will be
led by a male facilitator and female groups will be led by a
female facilitator. Facilitators will be motivated and pro-
vided with information and support through mobile
phone messages and by support visits by two female par-
ticipatory group coordinators based in Faridpur and a
community group manager based in Dhaka.
Health system strengthening
All study clusters (intervention and control) will receive
health system-strengthening activities. The reason to in-
clude a health system-strengthening component in our
study is twofold. First, there is the ethical imperative to
ensure that the control areas also benefit from the study.
Second, we expect some degree of a functioning ‘supply
side’ local health system to be necessary for the success
of the ‘demand side’ mHealth and community mobilisa-
tion interventions. Specific health system-strengthening
initiatives will be tailored according to the situation ana-
lysis conducted during the formative phase of the project
but are likely to include the training/refresher training of
formal and informal health care workers in the preven-
tion, diagnosis and treatment of T2DM, and the devel-
opment of essential equipment inventories.
Randomisation
Using available maps, 24 mauzas from each of the 4 upa-
zillas were purposefully selected on the basis of appearing
to avoid contiguity between mauzas. A single eligible
village within the selected mauza was designated the study
cluster. In this way, it was intended that all study villages
(clusters) would be separated from one another by a buffer
zone of mauzas and villages not included in the study.
By stratified randomisation, the 96 villages will be ran-
domly allocated to either the mHealth intervention arm,
the community mobilisation arm or the control arm (32
in each), with each upazilla constituting 1 stratum
(Fig. 3). The name of each village will be written on
pieces of paper, colour-coded by upazilla, which, when
folded, will be indistinguishable from each other. For
Phase 4
Evaluate & 
reflect on 
progress
Phase 1
Identify & 
prioritise 
problems
Phase 2
Plan strategies 
with the 
community
Phase 3
Put strategies 
into practice
Fig. 2 Four-phase participatory learning and action cycle underpinning the community mobilisation intervention
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each upazilla, the 24 folded pieces of paper will be
placed into a bottle and then drawn by community
leaders and representatives at a public community orienta-
tion meeting in Faridpur attended by the project director,
project manager and independent observers. The first
eight villages drawn from the bottle will be allocated to
‘arm A’, the next eight villages to ‘arm B’ and the final eight
villages to ‘arm C’. After all 96 villages have been allocated
to an arm, each of the 3 arms will be randomly assigned
to either the mHealth intervention, community group
intervention or control group by simultaneously drawing
arm letter and intervention allocation from 2 separate bot-
tles. The entire randomisation process will be filmed, and
photographs will be taken to document every stage.
Minimising contamination
Every effort was made using available maps and popula-
tion data to purposefully select study villages (clusters)
to be non-contiguous to minimise contamination be-
tween intervention clusters and between intervention
and control clusters. Further, exclusion of temporary or
migratory individuals from the study surveys will minim-
ise contamination between clusters.
Sample size
Sample size was determined using equations of Hayes and
Bennett [38] and Hayes and Moulton [39]. The trial, with
3 treatment arms, will include 32 mHealth intervention
clusters, 32 community mobilisation intervention clusters
and 32 control clusters, with an average population of 487
adults aged 30 years or older per cluster. As detailed in
the Background section above, estimates of intermediate
hyperglycaemia and T2DM prevalence in Bangladesh vary
[3–8]; therefore, our sample size calculation assumes a
mid-range baseline/control prevalence of 17%. In the ab-
sence of published values, using an estimated, moderate
between-cluster coefficient of variation (k) of 0.265, a
sample of 130 adults aged over 30 years per cluster will
give 80% power at 95% confidence to detect a minimum
of 21.5% reduction in disease prevalence in intervention
clusters relative to control clusters.
Assuming a baseline prevalence of abnormal fasting glu-
cose of 11%, the baseline surveys of 130 adults per cluster
will identify approximately 15 individuals with intermedi-
ate hyperglycaemia per cluster. With an assumed 25%
two-year cumulative incidence of T2DM among these
high-risk individuals, two-year follow-up will give our
study 78% power at 5% significance to detect a one-third
(33%) reduction in cumulative incidence in intervention
clusters relative to control clusters using a between-
cluster coefficient of variation of 0.265. An additional 10%
will be added to the sample list to allow for refusals, in-
ability to contact and loss to follow-up, bringing the total
target sample size to 143 per cluster, or 13,728.
Impact evaluation
Our trial has two primary outcomes. First is the com-
bined prevalence of intermediate hyperglycaemia (i.e.,
impaired fasting glucose or impaired glucose tolerance)
and T2DM among adults aged 30 years or older. We will
use WHO and International Diabetes Federation defini-
tions and blood glucose cut-offs for normoglycaemia,
impaired fasting glucose, impaired glucose tolerance and
T2DM, as summarised in Table 2 [40]. These levels have
been used in previous studies in Bangladesh and in other
Asian countries [3, 4].
Our second primary outcome is the cumulative 2-year
incidence of T2DM among individuals identified with
intermediate hyperglycaemia during our baseline survey.
Data collection and management
Sampling frame and sample
A sampling frame will be developed specifically for this
study by listing all households and their eligible
Fig. 3 D-Magic cluster randomised trial design
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members (non-pregnant permanent residents aged
30 years or older) within each of the study clusters. A
sample of 143 adults aged 30 years or older will be ran-
domly selected from this sampling frame from each
study cluster using multi-stage simple random sampling.
In the first stage, 143 households with at least 1 eligible
adult resident will be selected using probability propor-
tional to size sampling. At the next stage, a single eli-
gible adult will be selected for inclusion in the survey
using simple random sampling.
Surveys
Sampled individuals will be visited in their household and
informed of the study, and their verbal consent will be ob-
tained. Sampled individuals and data collectors are unlikely
to be aware of their village’s allocation to the intervention
or control arm at the time of the baseline survey, but they
are likely to be aware of allocation at the endline survey
owing to the unblended nature of allocation. All sampled
individuals in a single cluster will be informed of the an-
thropometric, blood glucose and blood pressure measure-
ment requirements of the study and will be requested to
attend a local centre on the morning of a specified day
following an overnight fast. The centre will be established
by the field team for the purposes of the study and will be
at a central, convenient location in the village. Collection of
questionnaire data will take place at the respondents’
homes before or after the physical measurements or at the
time of physical measurement in the testing centre.
Following extensive training and field practice, pairs of
trained fieldworkers (one male and one female) with at
least higher secondary school qualifications will be
trained to measure blood pressure, blood glucose con-
centration, body weight, height, and waist and hip girth
using standard methods. Blood pressure will be mea-
sured using the OMRON HBP 1100 Professional Blood
Pressure Monitor (OMRON Healthcare, Kyoto, Japan).
Two sitting measurements will be taken at approxi-
mately 5-minute intervals, and the respondent’s blood
pressure will be obtained by averaging these measure-
ments. Measurements of height, weight, and waist and
hip girth will be taken with subjects wearing light
clothes and without shoes. The weighing tools will be
calibrated daily by known weight. For height, the subject
will stand in erect posture vertically touching the occi-
put, back, hip and heels to the wall while gazing hori-
zontally in front and keeping the tragus and lateral
orbital margin in the same horizontal plane. Waist girth
will be measured by placing a non-stretchable plastic
tape horizontally midway between the 12th rib and the
iliac crest on the mid-axillary line. Similarly, hip circum-
ference will be measured by taking the extreme end pos-
teriorly and the symphysis pubis anteriorly. Physical
measurements will be recorded on specifically designed
forms and later entered into a mobile phone data entry
system.
Blood glucose will be measured using the OneTouch
Ultra glucometer (LifeScan, Inc., Milpitas, CA, USA) in
whole blood obtained by finger prick from capillaries in
the middle or ring finger after an overnight fast of 8–
12 h, an approach that is widely used in resource-limited
countries [4]. The OneTouch Ultra glucometer automat-
ically converts whole-blood glucose readings to the
equivalent plasma value, so no additional conversion will
be required. All individuals will then receive a 75-g
glucose load dissolved in 250 ml of water and will have a
repeat capillary blood test within 5 minutes of 120 -
minutes post-ingestion to determine glucose tolerance
status and differentiate between individuals with inter-
mediate hyperglycaemia and those with diabetes accord-
ing to WHO criteria (Table 2).
Detailed information on the socio-demographic char-
acteristics of all sampled individuals will be collected by
the trained fieldworkers using a structured survey in-
strument adapted from the WHO STEPwise tool [41]
and the 2011 Bangladesh Demographic and Health Sur-
vey [3]. The instrument will be designed to measure the
background demographic and socio-economic character-
istics, lifestyle and behavioural risk factors, diabetes
awareness indicators, health-seeking behaviour, and
costs of care-seeking among study participants. The EQ-
5D questionnaire will be used to measure quality of life
[42]. Questionnaire data will be gathered using Samsung
Galaxy Grand Prime (Samsung, Seoul, South Korea)
large-screen smartphones (US$200) using ODK Collect
open-source software.
Table 2 Glycaemia definitions and diagnostic criteria to be
used in the D-Magic trial
Definition Diagnostic criteria
Normoglycaemia Fasting plasma glucose
<6.1 mmol/L
Intermediate
hyperglycaemia
(sometimes termed
pre-diabetes)
Impaired
fasting
glucose
Fasting plasma glucose
≥6.1 mmol/L to
<7.0 mmol/L
and
Two-hour post-ingestion
of 75-g glucose load
plasma glucose <7.8 mmol/L
Impaired
glucose
tolerance
Fasting plasma glucose <7.0 mmol/L
and
Two-hour post-ingestion of 75-g
glucose load plasma glucose
≥7.8 mmol/L to <11.1 mmol/L
Type 2 diabetes mellitus Fasting plasma glucose ≥7.0 mmol/L
ora
Two-hour post-ingestion of 75-g
glucose load plasma glucose
≥11.1 mmol/L
Adapted from [40]
aDiabetes cannot be excluded without 2-h post-oral glucose load test
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Fieldworker activity will be monitored by a team of su-
pervisors with experience in field data collection and
survey techniques. Supervisors will observe data collec-
tion processes and conduct some repeat measurements
for verification in a random selection of cases. One
supervisor will have the sole responsibility of collecting
data from each individual fieldworker’s mobile phone
onto a laptop every 3 days (maximum) and transferring
these data to the district project office for data-checking
before final transfer of the data to Dhaka. Individuals
unable to participate in the data collection at the testing
centre or on the specified day will be followed and asked
to participate in the study at a later date.
Implementation research and process evaluation
Detailed quantitative and qualitative process evaluation
research will be done in intervention and control areas
throughout the trial to consider the effect of context on
interventions, to describe the implementation of the in-
terventions, and to help explain any observed interven-
tion effect or lack of effect. Process data will be used
throughout implementation to inform intervention de-
sign and delivery and will help to develop theory about
how the interventions impact health outcomes. This will
enable assessment of the feasibility, acceptability, scal-
ability and external validity (or replicability) of the
interventions.
Analysis
Interim analysis and stopping rules
A meeting of an independent Data and Safety Monitor-
ing Board (DSMB) will be convened according to the
DAMOCLES charter after entry and cleaning of baseline
survey data and approximately 9 months’ worth of im-
plementation and process data. The DSMB will be
tasked with providing an independent, objective review
of the study implementation and baseline data and ad-
vise on any extension or modification of the trial. In par-
ticular, it will review the following:
1. Process indicators, including community group
coverage, mHealth coverage (subscription rates) and
adherence to the implementation plan
2. The adequacy of the sample size and the validity of
sample size calculation assumptions about baseline
prevalence and incidence and intra-cluster correl-
ation coefficients
3. The comparability of treatment arms according to
baseline survey data
4. Data quality
5. Endline survey design
6. The proposed trial analysis plan, including methods
for adjustment of stratification and clustering and
intervention effect measures to be reported
Intervention allocation will be masked to the DSMB.
There are no stopping rules, because we do not expect
the intervention to have adverse effects at either the
cluster or participant level.
Intention-to-treat analysis
The trial will test the effect of a community mobilisation
intervention and an mHealth intervention, as described
previously, relative to a control group. We do not intend
to directly compare the effects of each intervention rela-
tive to the other. Analysis will be based on intention to
treat at the individual and cluster levels as appropriate
for the outcome measures. The intention-to-treat popu-
lation includes only adults aged 30 years or older who
are permanently residing in the village in which they are
surveyed. Participants with missing data on the primary
outcomes will be excluded from primary outcome ana-
lysis but may be included in secondary outcome analysis,
depending on data completeness. All analyses will be
carried out with adjustment for the stratified, clustered
study design, without and with adjustment for potential
confounders resulting from imbalance between study
clusters, which will be selected on the basis of their im-
portance as a determinant of the outcomes rather than
the size or significance of any difference between arms.
Estimates of the intervention effects will be presented
with 95% confidence intervals. No correction for multi-
plicity will be made. Analysis will be conducted using
STATA statistical software (StataCorp, College Station,
TX, USA).
Economic evaluation and equity impact analysis
Cost and cost-effectiveness analyses will take a societal
perspective, assessing the economic impact for all parties
affected by the interventions, including implementing
agencies (project or program costs), health care pro-
viders (at local and national levels), and users or house-
holds. Program costs will be collected prospectively
from the project accounts, and data on provider costs
will be collected retrospectively from a random sample
of primary care providers in the project area. Costs in-
curred by users or households will be collected during
household and other follow-up surveys. All costs will be
estimated from both a financial and an economic per-
spective, adjusted for inflation using the Bangladesh
Consumer Price Index (CPI) and presented in inter-
national dollars. Incremental cost-effectiveness ratios
will be evaluated in terms of the cost per case of inter-
mediate hyperglycaemia and T2DM prevented, cost per
case of diabetes prevented among individuals with inter-
mediate hyperglycaemia at baseline, cost per millimetre
of mercury reduction in systolic blood pressure, and
other secondary outcomes to be detailed in a separate
economic evaluation protocol to be submitted for
Fottrell et al. Trials  (2016) 17:600 Page 11 of 15
publication. The robustness of the cost-effectiveness
results will be assessed through a series of sensitivity
analyses. In addition to cost-effectiveness analysis, an
equity-impact analysis will be conducted to assess
whether the interventions have improved the equity of
health service delivery and are improving the health sta-
tus of those most in need.
Timetable
The intervention period is between June 2016 and
December 2017. A time schedule for project activities is
displayed in Fig. 4.
Ethics
Approvals
The trial has been reviewed and approved by the University
College London Research Ethics Committee (4766/002) and
by the BADAS Ethical Review Committee (BADAS-ERC/
EC/t5100246). The trial has been registered and assigned an
International Standard Randomised Controlled Trial num-
ber (ISRCTN41083256).
Community consultation
Community leaders will be identified and approached to
obtain permission to deliver the interventions and con-
duct the evaluation surveys. Orientation meetings will
be held to explain the project aims, and community
leaders will be invited to observe the randomisation
process. The concept of random sampling for inclusion
in the study surveys will be explained. Further,
community advisory committees composed of commu-
nity representatives and leaders will be established in
each study upazilla with the purpose of advising and
informing the research process and linking the research
team to the community [43, 44].
Consent
Individual participation in the community meetings and
receipt of the mHealth messages will be on a voluntary
basis, and participants can choose to withdraw from ei-
ther intervention at any time. Prior to all interviews and
focus group discussions, the purpose of the data collec-
tion will be explained, an information sheet will be pro-
vided, and consent from the interviewee will be
obtained. Respondents will be told that they can decline
to participate in the study and can refuse to answer any
question. Access to the identifiable individual-level data
will be restricted to surveillance and data entry staff as
well as analysts from the study team.
Treatment of illness in study areas
Fieldworkers will be trained to refer any individuals
identified with possible intermediate hyperglycaemia,
diabetes or hypertension to an appropriate health care
facility for consultation and confirmatory testing.
Benefits to control areas
We have equipoise on the interventions under test: the
effect of an mHealth messaging intervention or partici-
patory groups on T2DM and its risk factors is unknown
Fig. 4 Study time frame. DSMB Data and Safety Monitoring Board, PLA Participatory Learning and Action
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in the Bangladeshi context. It is therefore important to
test the effect of this intervention using a randomised
trial design. It is ethically important that the control
areas also benefit from the study. They will do so in two
ways. First, they will benefit directly through the health
system-strengthening activities that will be undertaken
in both study arms. Second, they will benefit indirectly
through the strengthening of the evidence base on the
burden of T2DM and its risk factors and our advocacy
activities at the local, national and international levels.
Scalability
The potential for scaling up the interventions under in-
vestigation in Bangladesh is high. Scale-up would be fa-
cilitated by the fact that the project partner (BADAS) is
the largest health care provider in Bangladesh after the
government and has strong links with government agen-
cies as well as private sector agents relevant to scale-up,
such as mobile telecommunications companies.
Role of funder
Peer review of the grant application influenced the de-
sign of the study and study outcomes. Beyond that, the
funder will have no role in the design of the study; the
data collection, analysis and interpretation; or the write-
up of the findings.
Dissemination
Successful completion of the Bangladesh D-Magic trial
will contribute to the science of the evaluation of complex
community-based interventions, behaviour change and
implementation research. Beyond these academic endeav-
ours, we anticipate that our study activities will benefit in-
dividuals and communities in our study areas, service
providers and policymakers in Bangladesh, and advocacy
and implementation groups tackling diabetes in
Bangladesh and internationally. Specifically, the data gen-
erated from the epidemiological description of the burden
of diabetes and its risk factors in Bangladesh, as well as
the anthropological perspectives added through formative
research, will deepen understanding of the issue within
the study context. Impact and process evaluation of two
discrete interventions will help to identify cost-effective
ways to address the burden of diabetes and non-
communicable disease risk factors in a low-income, rural
South Asian setting. Study activities and findings will be
disseminated to a range of audiences, including study par-
ticipants, service providers and policymakers, through a
range of appropriate means, including workshops, dissem-
ination meetings and peer-reviewed publications.
Discussion
This protocol describes the Bangladesh D-Magic trial
which, through implementation science methods,
mixedmethods process evaluation and rigorous impact
evaluation using a three arm cluster randomised con-
trolled design, will increase our understanding of diabetes
and other non-communicable disease burdens and risk
factors in rural Bangladesh. Study findings will provide
evidence on how population-level strategies of community
mobilisation and mHealth can be implemented to prevent
and control non-communicable diseases and risk factors
in this population.
Trial status
The trial is ongoing.
Endnotes
1We use the term intermediate hyperglycaemia to rep-
resent measures of glucose that are categorised as im-
paired fasting glucose or impaired glucose tolerance
according to the WHO definitions outlined in Table 2.
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